ArticleBritish journal of cancer1996
Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
Article in British journal of cancer, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 60 citations in OpenAlex.
- Review
- Riding the metalloproteinase roller coaster.The Journal of biological chemistry · 2017Article
- Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2016Review
- Animal models of colorectal peritoneal metastasis.Pleura and peritoneum · 2016Review
- Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro.BMC cancer · 2008Article
- A proteinase inhibitor decreases tumor growth in a laparoscopic rat model.Surgical endoscopy · 2001Article
- Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma.British journal of cancer · 2000Article
- Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.Annals of surgery · 2000Article
- Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer.Clinical & experimental metastasis · 1999Article
- Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.British journal of cancer · 1999Article
- Matrix metalloproteinase inhibitors: applications in oncology.Investigational new drugs · 1999Review
- Matrix metalloproteinases. Novel targets for directed cancer therapy.Drugs & aging · 1997Review
- Matrix metalloproteinase inhibitors: present achievements and future prospects.Investigational new drugs · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P < 0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P < 0.01) and 69% of control when administered from day 10 (P < 0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.